IP Library Granted Patent US 7,848,800
Granted Patent B2
US 7,848,800 · App. 10/492,494 · Granted Dec 7, 2010

Device for delivering medicines by transpalpebral electrophoresis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,848,800
App. No.
10/492,494
Granted
Dec 7, 2010
Kind
B2
Abstract

The invention concerns a device for ocular application of an active principle ( 1 ) comprising a main electrode ( 2 ) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone ( 21, 22 ) designed to be urged into contact with an eyelid.

Claims (31)

1. A device for ocular application of an active substance comprising a main electrode, the main electrode comprising:

(i) an insulating layer,

(ii) a conductive layer,

(iii) an electric lead sandwiched between the insulating layer and the conductive layer, wherein the electric lead is configured for connecting the main electrode to an external electrical feeding source,

(iv) an adhesive interlayer comprising material having adhesive properties for bonding the insulating layer to the conductive layer and for holding the electric lead onto the conductive layer, and

(v) a foam layer bonded to the conductive layer by a conductive adhesive layer, wherein the foam layer is an absorbent foam layer able to act as a reservoir for the active substance,

wherein the main electrode comprises a functional area configured to substantially cover an outer surface of an eyelid and which delivers the active substance through the eyelid onto the sclera of the eyeball and a non-functional central area.

2. A device according to claim 1 , wherein the main electrode is of oval overall shape.

3. A device according to claim 2 , wherein the oval shape has a large external diameter equal at most to approximately 40 mm and a small external diameter equal at most to approximately 35 mm.

4. A device according to claim 1 , wherein the non-functional central area overlays the cornea of a subject and the surrounding functional peripheral area overlays the area of the eye of the subject peripheral to the cornea when the electrode is placed in contact with the eyelid of a subject.

5. A device according to claim 4 , wherein the non-functional central area is of circular overall shape.

6. A device according to claim 5 , wherein the non-functional central area has a diameter equal at most to approximately 13 mm.

7. A device according to claim 4 , wherein the non-functional central area is a hole passing through the main electrode.

8. A device according to claim 1 , wherein the main electrode further comprises:

(vi) a cutaneous adhesive layer.

9. A device according to claim 1 , wherein the main electrode further comprises:

(vi) the conductive adhesive layer sandwiched between the foam layer and the conductive layer, comprising water insoluble material having adhesive properties for bonding the foam layer to the conductive layer.

10. A device according to claim 1 , wherein the main electrode is flexible.

11. A device according to claim 1 , wherein the insulating layer is a rigid casing.

12. A device according to claim 1 , wherein the active substance is applied by iontophoresis.

13. A device according to claim 1 , wherein the absorbent foam layer is an open-cell hydrophilic polyurethane foam.

14. A device according to claim 13 , wherein the absorbent foam layer has a density of 0.05 to 0.1 g/cm 3.

15. An electrode for the ocular application of an active substance comprising a main electrode, the main electrode comprising:

(i) an insulating layer,

(ii) a conductive layer,

(iii) an electric lead sandwiched between the insulating layer and the conductive layer, connecting the main electrode to an external electrical feeding source,

(iv) an adhesive interlayer comprising material having adhesive properties for bonding the insulating layer to the conductive layer and for holding the electric lead onto the conductive layer,

(v) a foam layer, wherein the foam layer is an absorbent foam layer able to act as a reservoir for the active substance,

(vi) a conductive adhesive layer sandwiched between the foam layer and the conductive layer, comprising water insoluble material having adhesive properties for bonding the foam layer to the conductive layer, and

(vii) a cutaneous adhesive layer adjacent to the foam layer and having adhesive properties for bonding the main electrode to the outer surface of the eyelid,

wherein the electrode comprises a functional area configured to substantially cover an outer surface of an eyelid and which delivers the active substance through the eyelid onto the sclera of the eyeball and a non functional central core.

Assignments (3)
CHANGE OF LEGAL ENTITY Recorded Jan 3, 2008
From: EYEGATE PHARMA S.A.
To: EYEGATE PHARMA S.A.S.
Reel/Frame 020312/0374 →
CHANGE OF NAME Recorded Oct 31, 2006
From: OPTIS FRANCE S.A.
To: EYEGATE PHARMA S.A.
Reel/Frame 018454/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2006
From: BEHAR-COHEN, FRANCINE; ROY, PIERRE
To: OPTIS FRANCE S.A.
Reel/Frame 018254/0279 →